Intracerebroventricular administration of metformin inhibits ghrelin-induced hypothalamic AMP-kinase signalling and food intake

Neuroendocrinology

Volumn 96, Issue 1, 2012, Pages 24-31

  Stevanovic, Darko ^a   Janjetovic, Kristina ^a   Misirkic, Maja ^a   Vucicevic, Ljubica ^a   Sumarac Dumanovic, Mirjana ^a   Micic, Dragan ^a   Starcevic, Vesna ^a   Trajkovic, Vladimir ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

AMPK; Food intake; Ghrelin; Hypothalamus; Metformin

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; GHRELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN REGULATORY ASSOCIATED PROTEIN; METFORMIN; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; FOOD INTAKE; HORMONE ACTION; HYPOTHALAMUS; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ACETYL-COA CARBOXYLASE; ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; EATING; GHRELIN; HYPOGLYCEMIC AGENTS; HYPOTHALAMUS; MALE; METFORMIN; RATS; RATS, WISTAR; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION;

EID: 84864880506     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000333963     Document Type: Article

References (47)

1. Correia S, Carvalho C, Santos MS, Seiça R, Oliveira CR, Moreira PI: Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem 2008; 8:1343-1354.
2. Golay A: Metformin and body weight. Int J Obes (Lond) 2008; 32:61-72.
3. Borst SE, Snellen HG, Lai HL: Metformin treatment enhances insulin-stimulated glucose t ranspor t i n skeleta l mu scle of Sprag ue-Dawley rats. Life Sci 2000; 67: 165-174.
4. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, Streicher P, Sieve-Smith L, Tracy TM, Lang JE, McCullough P: Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipopro-tein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism 2001; 50: 856-861.
5. Kumar VB, Bernardo AE, Vyas K, Franko M, Farr S, Lakshmanan L, Buddhiraju C, Mor-ley JE: Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci 2001; 69:2789-2799.
6. Lee A, Morley JE: Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-i nsu-lin-dependent diabetes. Obes Res 1998; 6: 47-53.
7. Matsui Y, Hirasawa Y, Sugiura T, Toyoshi T, Kyuki K, Ito M: Metformin reduces body weight gain and improves glucose intoler-ance in high-fat diet-fed C57BL/6J mice. Biol Pharm Bul l 2010; 33: 963-970.
8. Paolisso G, Amato L, Eccellente R, Gam-bardella A, Tagliamonte MR, Varricchio G, Carella C, Giugliano D, D'Onofrio F: Effect of metformin on food intake in obese subjects. Eur J Clin Invest 1998; 28: 441-446.
9. Rouru J, Huupponen R, Pesonen U, Koulu M: Subchronic treatment with metformin produces anorectic effect and reduces hyperin-sulinemia in genetically obese Zucker rats. Life Sci 1992; 50:1813-1820.
10. Łabuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B: Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010; 62: 956-965.
11. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH: Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes 2006; 55: 716-724.
12. Aubert G, Mansuy V, Voirol MJ, Pellerin L, Pralong FP: The anorexigenic effects of metformin involve increases in hypothalamic leptin receptor expression. Metabolism 2010; 60:327-334.
13. Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP: Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007; 148:507-511.
14. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fe-nyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
15. Hardie DG: AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obes (Lond) 2008; 32(suppl 4):S7-S12.
16. Harada S, Fujita-Hamabe W, Tokuyama S: The importance of regulation of blood glucose levels through activation of peripheral 5'-AMP-activated protein kinase on ischemic neuronal damage. Brain Res 2010; 1351: 254-263.
17. Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C, Bloom SR: Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) 2005; 29:1130-1136.
18. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S: A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-198.
19. Tang-Christensen M, Vrang N, Ortmann S, Bidlingmaier M, Horvath TL, Tschöp M: Central administration of ghrelin and agouti-related protein (83-132) increases food intake and decreases spontaneous locomotor activity in rats. Endocrinology 2004; 145: 4645-4652.
20. Tschöp M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-913.
21. Chen HY, Trumbauer ME, Chen AS, Wein-garth DT, Adams JR, Frazier EG, Shen Z, Marsh DJ, Feighner SD, Guan XM, Ye Z, Nargund RP, Smith RG, Van der Ploeg LH, Howard AD, MacNeil DJ, Qian S: Orexigen-ic action of peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. Endocrinology 2004; 145: 2607-2612.
22. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Haw-ley SA, Hardie DG, Grossman AB, Korbonits M: Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005; 280:25196-25201.
23. Andersson U, Filipsson K, Abbott CR, Woods A, Smith K, Bloom SR, Carling D, Small CJ: AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem 2004; 279: 12005-12008.
24. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferré P, Birnbaum MJ, Stuck BJ, Kahn BB: AMP-ki-nase regulates food intake by responding to hormonal and nutrient signals in the hypo-thala mus. Nature 2004; 428: 569-574.
25. Shaw RJ: LKB1 and AMP-activated protein kinase control of mTOR signaling and growth. Acta Physiol (Oxf) 2009; 196: 65-80.
26. Blouet C, Ono H, Schwartz GJ: Mediobasal hypothalamic p70 S6 kinase 1 modulates the control of energy homeostasis. Cell Metab 2008; 8:459-467.
27. Cota D, Matter EK, Woods SC, Seeley RJ: The role of hypothalamic mammalian target of rapamycin complex 1 signaling in diet-induced obesity. J Neurosci 2008; 28:7202-7208.
28. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, Woods SC, Seeley RJ: Hypotha-lamic mTOR signaling regulates food intake. Science 2006; 312: 927-930.
29. Doogue MP, Begg EJ, Moore MP, Lunt H, Pemberton CJ, Zhang M: Metformin increases plasma ghrelin in type 2 diabetes. Br J Clin Pharmacol 2009; 68:875-882.
30. Starcevic VP, Morrow BA, Farner LA, Keil LC, Severs WB: Long-term recording of ce-rebrospinal fluid pressure in freely behaving rats. Brain Res 1988; 462:112-117.
31. Petersen JS, DiBona GF: Acute sympathoin-hibitory actions of metformin in spontaneously hypertensive rats. Hypertension 1996; 27:619-625.
32. Morrison CD, Xi X, White CL, Ye J, Martin RJ: Amino acids inhibit Agrp gene expression via an mTOR-dependent mechanism. Am J Physiol Endocrinol Metab 2007; 293: E165-E171.
33. Anderson KA, Ribar TJ, Lin F, Noeldner PK, Green MF, Muehlbauer MJ, Witters LA, Kemp BE, Means AR: Hypothalamic CaMKK2 contributes to the regulation of en-erg y balance. Cell Metab 2008; 7: 377-388.
34. 2+ signaling via protein kinase A and N-type channel-dependent mechanisms and cross-talk with leptin and orex in. Diabetes 2003; 52: 948-956.
35. Velásquez DA, Martínez G, Romero A, Vázquez MJ, Boit KD, Dopeso-Reyes IG, López M, Vidal A, Nogueiras R, Diéguez C: The central Sirtuin 1/p53 pathway is essential for the orexigenic action of ghrelin. Diabetes 2011; 60:1177-1185.
36. Pinto S, Roseberry AG, Liu H, Diano S, Shanabrough M, Cai X, Friedman JM, Hor-vath TL: Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science 2004; 304: 110-115.
37. Potter WB, O'Riordan KJ, Barnett D, Osting SM, Wagoner M, Burger C, Roopra A: Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One 2010; 5:e8996.
38. Williams T, Courchet J, Viollet B, Brenman JE, Polleux F: AMP-activated protein kinase (AMPK) activity is not required for neuronal development but regulates axogenesis during metabolic stress. Proc Natl Acad Sci USA 2011; 108:5849-5854.
39. Villanueva EC, Münzberg H, Cota D, Leshan RL, Kopp K, Ishida-Takahashi R, Jones JC, Fingar DC, Seeley RJ, Myers MG Jr: Complex regulation of mammalian target of rapamy-cin complex 1 in the basomedial hypothala-mus by leptin and nutritional status. Endocrinology 2009; 150:4541-4551.
40. Moesgaard SG, Ahrén B, Carr RD, Gram DX, Brand CL, Sundler F: Effects of high-fat feeding and fasting on ghrelin expression in the mouse stomach. Reg ul Pept 2004; 120: 261-267.
41. Toshinai K, Date Y, Murakami N, Shimada M, Mondal MS, Shimbara T, Guan JL, Wang QP, Funahashi H, Sakurai T, Shioda S, Mat-sukura S, Kangawa K, Nakazato M: Ghrelin-induced food intake is mediated via the orex-in pathway. Endocrinology 2003; 144:1506-1512.
42. Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R: Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent. J Cell Biol 2002; 159:217-224.
43. Andrews ZB, Liu ZW, Walllingford N, Erion DM, Borok E, Friedman JM, Tschöp MH, Shanabrough M, Cline G, Shulman GI, Coppola A, Gao XB, Horvath TL, Diano S: UCP2 mediates ghrelin's action on NPY/AgRP neurons by lowering free radicals. Nature 2008; 454:846-851.
44. López M, Lage R, Saha AK, Pérez-Tilve D, Vázquez MJ, Varela L, Sangiao-Alvarellos S, Tovar S, Raghay K, Rodríguez-Cuenca S, Deoliveira RM, Castañeda T, Datta R, Dong JZ, Culler M, Sleeman MW, Alvarez CV, Gallego R, Lelliott CJ, Carling D, Tschöp MH, Dié-guez C, Vidal-Puig A: Hypothalamic fatty acid metabolism mediates the orexigenic action of ghrelin. Cell Metab 2008; 7: 389-399.
45. Lage R, Vázquez MJ, Varela L, Saha AK, Vi-dal-Puig A, Nogueiras R, Diéguez C, López M: Ghrelin effects on neuropeptides in the rat hypothalamus depend on fatty acid metabolism actions on BSX but not on gender. FASEB J 2010; 24: 2670-2679.
46. Rouru J, Pesonen U, Koulu M, Huupponen R, Santti E, Virtanen K, Rouvari T, Jhanwar-Uniyal M: Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y. Eur J Pharmacol 1995; 273: 99-106.
47. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM: Clinical phar-macokinetics of metformin. Clin Pharmaco-k inet 2011; 50: 81-98.